Former CEO Peter Greenleaf files intent to sell $49.7M in shares
Summary
Former CEO Peter Greenleaf intends to sell $49.7 million in Aurinia Pharmaceuticals shares, a significant transaction following recent leadership changes.
Key Events
-
Intent to Sell Shares
Peter Greenleaf, a former affiliate (previously CEO), filed a Form 144 to sell 3,136,201 common shares.
-
Significant Transaction Value
The proposed sale has an approximate market value of $49,677,423.84, representing about 2.44% of the company's outstanding shares.
-
Cashless Option Exercise
The sale is described as a cashless exercise of options and subsequent sale, often for liquidity or tax planning.
-
Follows Leadership Transition
This filing by the former CEO follows a recent executive leadership overhaul where Kevin Tang was appointed CEO on March 23, 2026.
Analysis
Former CEO Peter Greenleaf has filed a Form 144 indicating his intent to sell approximately $49.7 million worth of shares, representing about 2.46% of the company's outstanding shares. This sale is described as a cashless exercise of options and subsequent sale. While often pre-planned for liquidity or tax purposes, the substantial size of this transaction from a former executive is notable, especially following the recent executive leadership overhaul where Kevin Tang took over as CEO.
At the time of this filing, AUPH was trading at $15.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.